» Articles » PMID: 19622045

HIV Subtype D is Associated with Dementia, Compared with Subtype A, in Immunosuppressed Individuals at Risk of Cognitive Impairment in Kampala, Uganda

Overview
Journal Clin Infect Dis
Date 2009 Jul 23
PMID 19622045
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In the United States, clade B is the predominant human immunodeficiency virus (HIV) subtype, whereas in sub-Saharan Africa, clades A, C, and D are the predominant subtypes. HIV subtype may have an impact on HIV disease progression. The effect of HIV subtype on the risk of dementia has, to our knowledge, not been examined. The objective of this study was to examine the relationship between HIV subtype and the severity of HIV-associated cognitive impairment among individuals initiating antiretroviral therapy in Uganda.

Methods: Sixty antiretroviral-naive HIV-infected individuals with advanced immunosuppression who were at risk of HIV-associated cognitive impairment underwent neurological, neuropsychological, and functional assessments, and gag and gp41 regions were subtyped. Subtype assignments were generated by sequence analysis using a portion of the gag and gp41 regions.

Results: Thirty-three HIV-infected individuals were infected with subtype A, 2 with subtype C, 9 with subtype D, and 16 with A/D recombinants. Eight (89%) of 9 HIV-infected individuals with subtype D had dementia, compared with 7 (24%) of 33 HIV-infected individuals with subtype A (P = .004).

Conclusions: These results suggest that, in untreated HIV-infected individuals with advanced immunosuppression who are at risk of developing HIV-associated cognitive impairment, HIV dementia may be more common among patients infected with subtype D virus than among those infected with subtype A virus. These findings provide the first evidence, to our knowledge, to demonstrate that HIV subtypes may have a pathogenetic factor with respect to their capacity to cause cognitive impairment. Additional studies are needed to confirm this observation and to define the mechanism by which subtype D leads to an increased risk of neuropathogenesis.

Citing Articles

A pilot investigation of the association between HIV-1 Vpr amino acid sequence diversity and the tryptophan-kynurenine pathway as a potential mechanism for neurocognitive impairment.

Asia L, Jansen Van Vuren E, Lindeque Z, Williams M Virol J. 2024; 21(1):47.

PMID: 38395987 PMC: 10893664. DOI: 10.1186/s12985-024-02313-1.


The relationship between HIV-1 neuroinflammation, neurocognitive impairment and encephalitis pathology: A systematic review of studies investigating post-mortem brain tissue.

Williams M, Naude P Rev Med Virol. 2024; 34(1):e2519.

PMID: 38282400 PMC: 10909494. DOI: 10.1002/rmv.2519.


Implications of the 375W mutation for HIV-1 tropism and vaccine development.

Verdejo-Torres O, Vargas-Pavia T, Fatima S, Clapham P, Duenas-Decamp M J Virol. 2024; 98(1):e0152223.

PMID: 38169306 PMC: 10804988. DOI: 10.1128/jvi.01522-23.


Sex differences in cognitive function among people with HIV-1 clade C infection in Northern India.

Sharma A, Mohanty M, Salan T, Aggarwal D, Mandell L, Jones D J Neurovirol. 2023; 29(5):614-625.

PMID: 37698788 DOI: 10.1007/s13365-023-01166-8.


Transmitted/founder SHIV.D replicates in the brain, causes neuropathogenesis, and persists on combination antiretroviral therapy in rhesus macaques.

Podgorski R, Robinson J, Smith M, Mallick S, Zhao H, Veazey R Retrovirology. 2023; 20(1):13.

PMID: 37563642 PMC: 10413509. DOI: 10.1186/s12977-023-00628-5.


References
1.
Simon V, Ho D . HIV-1 dynamics in vivo: implications for therapy. Nat Rev Microbiol. 2004; 1(3):181-90. DOI: 10.1038/nrmicro772. View

2.
Pillai S, Kosakovsky Pond S, Liu Y, Good B, Strain M, Ellis R . Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain. 2006; 129(Pt 7):1872-83. DOI: 10.1093/brain/awl136. View

3.
Lole K, Bollinger R, Paranjape R, Gadkari D, Kulkarni S, Novak N . Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol. 1998; 73(1):152-60. PMC: 103818. DOI: 10.1128/JVI.73.1.152-160.1999. View

4.
Liner 2nd K, Hall C, Robertson K . Impact of human immunodeficiency virus (HIV) subtypes on HIV-associated neurological disease. J Neurovirol. 2007; 13(4):291-304. DOI: 10.1080/13550280701422383. View

5.
Ritola K, Robertson K, Fiscus S, Hall C, Swanstrom R . Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol. 2005; 79(16):10830-4. PMC: 1182623. DOI: 10.1128/JVI.79.16.10830-10834.2005. View